Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages in vitro

Journal of Neuroimmunology

Volumn 199, Issue 1-2, 2008, Pages 24-34

  DaSilva, Angelika Goncalves ^a,b   Yong, V Wee ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis; Metalloproteinases; Neuroinflammation; Proteases

Indexed keywords

INTERLEUKIN 1BETA; MACROPHAGE ELASTASE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; INTERFERON TYPE II; INTERLEUKIN-1BETA; MACROPHAGES; MATRIX METALLOPROTEINASE 12; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47549106469     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.034     Document Type: Article

References (54)

1. Agrawal S., Anderson P., Durbeej M., van Rooijen N., Ivars F., Opdenakker G., and Sorokin L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203 (2006) 1007-1019
2. Anthony D.C.C., Ferguson B., Matyzak M.K., Millert K.M., Esiri M.M., and Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23 (1997) 406-415
3. Avolio C., Filippi M., Tortorella C., Rocca M.A., Ruggieri M., Agosta F., Tomassini V., Pozzilli C., Stecchi S., Giaquinto P., Livrea P., and Trojano M. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult. Scler. 11 (2005) 441-446
4. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., and Wee Yong V. Targeting leukocyte MMPs and transmigration Minocycline as a potential therapy for multiple sclerosis. Brain 125 (2002) 1297-1308
5. Bruno M.A., and Cuello A.C. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6735-6740
6. Campbell E.J., Cury J.D., Shapiro S.D., Goldberg G.I., and Welgus H.G. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J. Immunol. 146 (1991) 1286-1293
7. Canete Soler R., Gui Y.H., Linask K.K., and Muschel R.J. MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Brain Res. Dev. Brain Res. 88 (1995) 37-52
8. Canete-Soler R., Gui Y.H., Linask K.K., and Muschel R.J. Developmental expression of MMP-9 (gelatinase B) mRNA in mouse embryos. Dev. Dyn. 204 (1995) 30-40
9. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C.C., Adams S.E., and Gearing A.J.H. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72 (1997) 155-161
10. Chen X., Howard O.M., and Oppenheim J.J. Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J. Immunol. 178 (2007) 6123-6129
11. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van der Walk P., and De Groot C.J.A. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 94 (1997) 590-598
12. Foss D.L., Baarsch M.J., and Murtaugh M.P. Regulation of hypoxanthine phosphoribosyltransferase, glyceraldehyde-3-phosphate dehydrogenase and beta-actin mRNA expression in porcine immune cells and tissues. Anim. Biotechnol. 9 (1998) 67-78
13. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006) 942-955
14. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., and Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50 (2001) 443-451
15. Giambernardi T.A., Grant G.M., Taylor G.P., Hay R.J., Maher V.M., McCormick J.J., and Klebe R.J. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 16 (1998) 483-496
16. Gijbels K., Galardy R.E., and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94 (1994) 2177-2182
17. Giuliani F., Metz L.M., Wilson T., Fan Y., Bar-Or A., and Yong V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158 (2005) 213-221
18. Hayashita-Kinoh H., Kinoh H., Okada A., Komori K., Itoh Y., Chiba T., Kajita M., Yana I., and Seiki M. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth Differ. 12 (2001) 573-580
19. Hewson A.K., Smith T., Leonard J.P., and Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44 (1995) 345-349
20. Hu J., Van den Steen P.E., Sang Q.X., and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6 (2007) 480-498
21. Kerkela E., Bohling T., Herva R., Uria J.A., and Saarialho-Kere U. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone 29 (2001) 487-493
22. Kerkela E., Ala-aho R., Klemi P., Grenman S., Shapiro S.D., Kahari V.M., and Saarialho-Kere U. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J. Pathol. 198 (2002) 258-269
23. Kieseier B.C., Seifert T., Giovannoni G., and Hartung H.P. Matrix metalloproteinases in inflammatory demyelination: tragets for treatment. Neurology 53 (1999) 20-25
24. Kouwenhoven M., Ozenci V., Gomes A., Yarilin D., Giedraitis V., Press R., and Link H. Multiple sclerosis: elevated expression of matrix metalloproteinases in boold monocytes. J. Autoimmun. 16 (2001) 463-470
25. Kouwenhoven M., Ozenci V., Tjernlund A., Pashenkov M., Homman M., Press R., and Link H. Monocyte-derived dendritic cells express and secret matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. J. Neuroimmunol. 126 (2002) 161-171
26. Lang R., Kocourek A., Braun M., Tschesche H., Huber R., Bode W., and Maskos K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J. Mol. Biol. 312 (2001) 731-742
27. Larsen P.H., DaSilva A.G., Conant K., and Yong V.W. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 26 (2006) 2207-2214
28. Lee R., Kermani P., Teng K.K., and Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 294 (2001) 1945-1948
29. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40 (1996) 846-852
30. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J., and Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44 (1998) 35-46
31. Lindberg R.L., De Groot C.J., Montagne L., Freitag P., van der Valk P., Kappos L., and Leppert D. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124 (2001) 1743-1753
32. Messmer U.K., and Brune B. Modification of macrophage glyceraldehyde-3-phosphate dehydrogenase in response to nitric oxide. Eur. J. Pharmacol. 302 (1996) 171-182
33. Opdenakker G., Nelissen I., and Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2 (2003) 747-756
34. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., and Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152 (1998) 729-741
35. Parks W.C., Wilson C.L., and Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4 (2004) 617-629
36. Proost P., Van Damme J., and Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192 (1993) 1175-1181
37. Rosenberg G.A. Matrix metalloproteinases in multiple sclerosis: is it time for a treatment trial?. Ann. Neurol. 50 (2001) 431-433
38. Saha R.N., and Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid. Redox Signal. 8 (2006) 929-947
39. Sekine-Aizawa Y., Hama E., Watanabe K., Tsubuki S., Kanai-Azuma M., Kanai Y., Arai H., Aizawa H., Iwata N., and Saido T.C. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur. J. Neurosci. 13 (2001) 935-948
40. Shipley J.M., Wesselschmidt R.L., Kobayashi D.K., Ley T.J., and Shapiro S.D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3942-3946
41. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
42. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17 (2001) 463-516
43. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., and Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40 (1996) 853-863
44. Szklarczyk A., Lapinska J., Rylski M., McKay R.D., and Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 22 (2002) 920-930
45. Toft-Hansen H., Nuttall R.K., Edwards D.R., and Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 173 (2004) 5209-5218
46. Toft-Hansen H., Buist R., Sun X.J., Schellenberg A., Peeling J., and Owens T. Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system. J. Immunol. 177 (2006) 7242-7249
47. Tonon S., Badran B., Benghiat F.S., Goriely S., Flamand V., Willard-Gallo K., Willems F., Goldman M., and De Wit D. Pertussis toxin activates adult and neonatal naive human CD4 + T lymphocytes. Eur. J. Immunol. 36 (2006) 1794-1804
48. Ulrich R., Gerhauser I., Seeliger F., Baumgartner W., and Alldinger S. Matrix metalloproteinases and their inhibitors in the developing mouse brain and spinal cord: a reverse transcription quantitative polymerase chain reaction study. Dev. Neurosci. 27 (2005) 408-418
49. Vos C.M.P., van Haastert E.S., De Groot C.J.A., Van der Walk P., and de Vries H.E. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active mutliple sclerosis lesions. J. Neuroimmunol. 138 (2003) 106-114
50. Weaver A., Goncalves da Silva A., Nuttall R.K., Edwards D.R., Shapiro S.D., Rivest S., and Yong V.W. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J. 19 (2005) 1668-1670
51. Wu L., Tanimoto A., Murata Y., Fan J., Sasaguri Y., and Watanabe T. Induction of human matrix metalloproteinase-12 gene transcriptional activity by GM-CSF requires the AP-1 binding site in human U937 monocytic cells. Biochem. Biophys. Res. Commun. 285 (2001) 300-307
52. Xie S., Issa R., Sukkar M.B., Oltmanns U., Bhavsar P.K., Papi A., Caramori G., Adcock I., and Chung K.F. Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cells. Respir. Res. 6 (2005) 148
53. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. 2 (2001) 502-511
54. Yong V.W., Giuliani F., Xue M., Bar-Or A., and Metz L.M. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 68 (2007) S32-S37 discussion S43-54